Small-cap stocks often fly under the radar, but some are now drawing attention from Wall Street. Analysts have identified three Russell 2000 companies with strong fundamentals and growth potential, each offering more than 100% upside from current levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Let’s dive into the details. Click on any ticker to explore each stock further and decide if it deserves a spot in your portfolio.
Beam Therapeutics (BEAM)
Beam Therapeutics is a biotechnology company focused on precision genetic medicines. Year-to-date, BEAM stock has declined by over 14%.
Overall, 11 out of 13 analysts rate BEAM stock as a Buy. The average Beam Therapeutics’ stock price target of $45 implies a potential upside of 112% from current levels.
Lantheus (LNTH)
Lantheus Holdings is a radiopharmaceutical company that makes imaging agents and AI-powered diagnostic tools. Year-to-date, LNTH stock has declined by over 18%.
Wall Street analysts stay highly bullish on LNTH stock, with eight out of nine analysts rating it as Buy. Meanwhile, the Lantheus price target of $160.67 implies an upside of over 120% from current levels.
Apogee Therapeutics (APGE)
Apogee Therapeutics is a clinical-stage biotech company focused on developing novel biologic therapies for inflammatory and immunological diseases.
Recently, four-star-rated analyst Tim Anderson at Bank of America Securities reiterated his Buy rating on APGE stock, predicting a growth rate of 90% over current levels. Overall, the stock has unanimous Buy recommendations from all nine analysts covering it. Apogee’s average stock price target of $96.75 suggests a potential upside of 138% from current levels.
